Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.34 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.34 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30867732 | 0.79 | TP53 (0.48) | THRBTP53LMNA | |
| SCHEMBL30867823 | 0.77 | GPR119 (0.37) | GPR119THRBTP53LMNA | |
| SCHEMBL30911193 | 0.77 | GPR119 (0.37) | GPR119THRBTP53LMNA | |
| SCHEMBL38654232 | 0.75 | LMNA (0.36) | MAPTTHRBTP53LMNA | |
| SCHEMBL38653231 | 0.71 | LMNA (0.46) | MAPTTHRBTP53LMNA | |
| SCHEMBL17802843 | 0.67 | CHRM2 (0.51) | CHRM2CHRM1CHRM3GPR119KCNK3 | |
| SCHEMBL30872476 | 0.67 | POLB (0.48) | MAPTTHRBTP53LMNA | |
| SCHEMBL38653670 | 0.67 | MEN1 (0.48) | THRBTP53LMNA | |
| SCHEMBL17705982 | 0.67 | CHRM2 (0.54) | CHRM2CHRM1CHRM3GPR119KCNK3 | |
| SCHEMBL21314139 | 0.67 | CHRM2 (0.73) | CHRM2CHRM1CHRM3GPR119KCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | KRAS, NRAS, HRAS | CHRM2 4411/4885CHRM1 4160/4885CHRM3 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.